PSNL News and Press, Personalis Inc.

2026-06-29 17:20:00 ET A week ago, I wrote that leadership had left the mega-cap “generals” and split into two baskets: semiconductors (velocity) and regional banks (breadth). That’s still true. But the dashboard has been quietly flagging a third group climbing the ...

2026-06-25 13:28:01 ET Healthcare ETFs: ( XLV ), ( VHT ), ( IYH ), ( XHE ), ( IHI ), ( XBI ), ( PBE ), ( IDNA ) ...

2026-06-12 07:57:50 ET Investment thesis Caris Life Sciences ( CAI ) combines 79% revenue growth in Q1 2026, positive free cash flow and gross margins above 65%. Beyond its diagnostic tests, the company has built a genomic database of more than one million profiled cases that ma...

Regulatory milestone for specimen collection kits enables global deployment of Personalis’ ultrasensitive MRD detection (Next Personal®) for drug development programs Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced tha...

2026-06-04 10:51:07 ET Christopher M. Hall, Chief Executive Officer of Personalis (NASDAQ:PSNL) , disclosed the direct exercise and immediate sale of 100,000 shares of Common Stock, valued at approximately $1.10 million, in a transaction reported on May 29, 2026. SEC Form 4 filing...

NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery Ultrasensitive NeXT Personal performance was demonstrated across 6 different solid tumor types Personalis, Inc. (Nasdaq: PSNL) today ...

2026-05-28 17:14:55 ET Overview - Brief History Of Personalis Fremont, California-based Personalis, Inc. ( PSNL ) completed its Initial Public Offering ("IPO") in June 2019, raising ~$135m via the issuance of ~7.92m shares priced at $17 per share. In a press release , th...

Abstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal ...

2026-05-20 08:38:37 ET More on Personalis Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript Personalis rises as Medicare coverage for NeXT Personal test expands Personalis outlines 2026 clinical ...

Expanded coverage enables Medicare beneficiaries with Stage II-III TNBC or HER2+ breast cancer to access ultrasensitive MRD testing to monitor response to neoadjuvant therapy Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that th...